Koers MiMedx Group Inc Nasdaq
Aandelen
US6024961012
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 361 mln. 336 mln. | Omzet 2025 * | 406 mln. 377 mln. | Marktkapitalisatie | 1,1 mld. 1,02 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 45 mln. 41,79 mln. | Nettowinst (verlies) 2025 * | 55 mln. 51,07 mln. | EV/omzet 2024 * | 3,04 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,71 x |
K/w-verhouding 2024 * |
23,8
x | K/w-verhouding 2025 * |
18
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,76% |
Recentste transcriptie over MiMedx Group Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 27-01-23 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 05-07-23 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 02-07-20 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 08-03-21 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-22,03% | 126 mln. | |
+3,72% | 75,91 mln. | |
+5,15% | 60,02 mln. | |
-1,20% | 51,7 mln. |